“On-target development – Specificity screening of biotherapeutics”

Recording of July 2020 webinar

Featured presentations:

“True specificity is a critical development characteristic in therapeutic antibody development” Jonny Finlay, PhD – CEO, UltraHuman Limited

“Off-target Screening: A Pharma Industry Perspective” Martin Scott, PhD – Scientific Leader and Associate Fellow, GSK

“Cell Microarray technology in specificity screening” Nick Brown, MSc – Retrogenix Limited

  • Understand how data generated with Cell Microarray screening is used in lead selection and safety assessment
  • Explore how specificity data supports IND submissions as either an adjunct to, or replacement for, tissue cross reactivity studies
  • Learn more about identifying and mitigating the risk of clinical toxicity caused by off-target effects of monoclonal antibodies.

Why use Retrogenix?

Ensuring that a novel biotherapeutic is specific to its intended target is undoubtedly advantageous when selecting promising lead candidates, however, it becomes vital when assessing potential safety implications prior to clinical studies.

Retrogenix specificity screening data has been readily accepted in applications for clinical trials and marketing approval in the US, Europe, China & Japan. Further details can be found in our case study using the link below. Or, to find out more, please get in touch with a member of our team.

 

Retrogenix data in regulatory submissions

Get In Touch
Pfizer
The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
BioInvent
AstraZeneca
Bluebird Bio
glycotope_logo
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
MedImmune
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
Capella Bioscience Logo
Sanofi Logo
Unum Theraputics Logo
Celyad Logo
We were impressed with the power of the Retrogenix technology in terms of on/off target characterization of early drug candidates. Their quick turnaround time and excellent, proactive communication was a real pleasure.
Dr. Bernd Schlereth, Senior Director Nonclinical Safety, Covagen